Last month, it was reported that IBM would stop selling Watson for Drug Discovery, but executives in the field of biopharma artificial intelligence say the field is still going strong.
In a CNBC interview, Chamath Palihapitiya, CEO and founder of Social Capital, shot down IBM and its Watson platform.
Artificial intelligence and concerns over the long term consequences has come up again in the news week in the form of a Scientific American blog musing over how artificial intelligence will evolve — “Is AI Dangerous? It Depends…” There is a certain amount of hand wringing over AI and, to a lesser extent, its branches […]
The Mayo Clinic announced a new partnership with IBM’s Watson data analytics platform that promises to match patients to the best clinical trials. The Clinic made the announcement at its annual Transform conference in Rochester, Minnesota. Starting in 2015, what IBM calls cognitive computing will be introduced into clinical use, specifically on cancer trials. “In […]
Johnson & Johnson and Sanofi are using IBM Watson’s computer brain/big data cruncher to support research and development. It will be used to identify new applications for drugs that have already been developed and to leaf through scientific papers that detail clinical trial outcomes, according to a statement from IBM. The partnerships follow a new […]
An innovation throwdown by IBM asked companies to devise mobile applications tapping Watson’s cognitive computing technology. After the finalists submit prototypes for judging, only five teams will present proposals to IBM. The three winners are awarded 90 days of access to the Watson APIs and consulting from IBM Interactive design services. Of the 25 businesses […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Today IBM will announce a version of Watson that’s cloud-based and twice as powerful at a cheaper cost, the New York Times reports. Not only will small businesses, academics and software developers be able to beat their friends to the answers while watching Jeopardy, it could have a significant impact on the future of healthcare. […]
One year into a research partnership with Cleveland Clinic, IBM and its famed supercomputing software Watson are making headway on helping clinicians with two great healthcare challenges: using electronic health data to its full potential and making the most informed diagnosis. The former is taking shape in a project called Watson EMR Assistant, which combines […]
Supercomputer and former Jeopardy! contestant Watson is the focus of a new Cleveland Clinic-IBM partnership that will teach Watson about medicine and help it become a clinical decision support tool for future doctors. IBM announced today that a team of researchers will work with physicians, faculty and medical students at the Cleveland Clinic Lerner College […]
Three U.S. senators are raising questions with Pfizer (NYSE:PFE) over its deal making for its mega-blockbuster cholesterol drug Lipitor as generic drug makers step up to market the drug, most recently Ranbaxy Laboratories, an India-based generic drug developer. Max Baucus (D-Montana), Chuck Grassley (R-Iowa) and Herb Kohl (D-Wisconsin) are concerned that Pfizer’s deals with pharmacy […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
